RxDoctor Payments Data

Travis Hays, MD

Infectious Disease · Fort Wayne, INNPI 1609040112

Payments from drug & device makers

$687in general payments, 2019–2025

Across 38 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$310
  • Paratek Pharmaceuticals, Inc.$62
  • Gilead$59
  • Merck$57
  • Melinta Therapeutics, LLC$41
  • Astellas Pharma US Inc$36
  • plus $122 from 6 others

What the payments were for

  • Food & beverage$687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$687 in reported general payments places this provider in the 55th percentile of 152 infectious disease providers in Indiana.

See all infectious disease providers in Indiana

Medicare billing

Part B allowed, 2024
$59,621
Medicare patients
136
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala35$148,096
TriumeqAbacavir/Dolutegravir/Lamivudi24$88,498
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$56,617
Daptomycin14$38,911
DovatoDolutegravir Sodium/Lamivudine11$37,484
PrezcobixDarunavir/Cobicistat11$28,655
TivicayDolutegravir Sodium11$26,228
DescovyEmtricitabine/Tenofov Alafenam11$25,588
ErtapenemErtapenem Sodium24$21,421
CeftriaxoneCeftriaxone Sodium32$3,597
Doxycycline Hyclate27$2,251
Vancomycin Hcl13$1,940
Cefazolin Sodium15$605
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$571
Cephalexin19$409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$59$173,68446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 152 infectious disease providers in Indiana.

Other infectious disease in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →